GoodRx (Nasdaq: GDRX) announced it is working with ARS Pharmaceuticals to offer the lowest discounted cash price for neffy in ...

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced it is working with ARS ...

Neffy, an intranasal formulation of epinephrine, is now available for emergency treatment of type I allergic reactions.

ARS Pharmaceuticals Inc. submitted a supplemental New Drug Application (sNDA) for a1 mg dose of nasal spray neffy, to treat ...

Whether it’s allergies, a sinus infection or runny nose, many people turn to nasal sprays for quick relief. Now, there’s ...

The submission of the neffy 1 mg sNDA follows the FDA approval of neffy (2 mg) on August 9, 2024, for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing 30 kg ...

We came across a bullish thesis on ARS Pharmaceuticals (SPRY) on Value Degen’s Substack by Unemployed Value Degen. In this ...

Now, doctors and researchers are working on other vaccines that would be beneficial in nasal spray form. Dr. Curiel says ...

Neffy is a small molecule commercialized by ARS Pharmaceuticals, with a leading Pre-Registration program in Anaphylaxis.

Human factor studies showed that adults without knowledge of the disease or device (e.g. a babysitter or a teacher), were able to successfully use the device by simply reading the instructions. These ...

Whether it’s allergies, a sinus infection or runny nose many people turn to nasal sprays for quick relief. And now, there’s ...